(Press-News.org) CHICAGO – Among patients with relapsing-remitting multiple sclerosis (MS), treatment with the widely-prescribed drug to treat MS, interferon beta, was not associated with less progression of disability, according to a study in the July 18 issue of JAMA.
"A key feature of MS is clinical progression of the disease over time manifested by the accumulation of disability. Interferon beta drugs are the most widely prescribed disease-modifying drugs approved by the U.S. Food and Drug Administration for the treatment of relapsing-onset MS, the most common MS disease course," according to background information in the article. The authors add that there is a lack of well-controlled longitudinal studies investigating the effect of interferon beta on disability progression.
Afsaneh Shirani, M.D., of the University of British Columbia, Vancouver, Canada, and colleagues conducted a study to investigate the association between interferon beta exposure and disability progression in relapsing-remitting MS. The study included prospectively collected data (1985-2008) from British Columbia. Patients with relapsing-remitting MS treated with interferon beta (n = 868) were compared with untreated contemporary (n = 829) and historical (prior to the approval of interferon beta) (n = 959) groups. The primary outcome measured was time from interferon beta treatment eligibility (baseline) to a confirmed and sustained score of 6 (requiring a cane to walk 100 meters; confirmed at >150 days with no measurable improvement) on the Expanded Disability Status Scale (EDSS) (range, 0-10, with higher scores indicating higher disability).
Follow-up time (first to last EDSS measurement) differed between groups, being considerably longer for the historical untreated cohort (median [midpoint], 10.8 years), who by definition entered the study much earlier than the contemporary cohorts. The median follow-up times for the contemporary cohorts were 5.1 years for the treated group and 4.0 years for the untreated group.
The observed outcome rates for reaching a sustained EDSS score of 6 were 10.8 percent in the treated group; 5.3 percent in the contemporary untreated group; and 23.1 percent in the historical untreated group.
"After adjustment for potential baseline confounders (sex, age, disease duration, and EDSS score), exposure to interferon beta was not associated with a statistically significant difference in the hazard of reaching an EDSS score of 6 when either the contemporary control cohort or the historical control cohort were considered," the researchers write. Further adjustment for co-existing illnesses and socioeconomic status, where possible, did not change interpretations.
"In conclusion, we did not find evidence that administration of interferon beta was associated with a reduction in disability progression in patients with relapsing-remitting MS. The ultimate goal of treatment for MS is to prevent or delay long-term disability. Our findings bring into question the routine use of interferon beta drugs to achieve this goal in MS. It is, however, possible that a subgroup of patients benefit from interferon beta treatment and that this association would not be discernable in our comprehensive 'real-world' study. Further work is needed to identify these potential patients; perhaps through pharmacogenomic or biomarker studies, paving the way for a tailored, personalized medicine approach. Our findings also encourage the investigation of novel therapeutics for MS."
(JAMA. 2012;308[3]:247-256. Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Please Note: For this study, there will be multimedia content available, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 3 p.m. CT Tuesday, July 17 at this link.
Editorial: Evaluating the Potential Benefit of Interferon Treatment in Multiple Sclerosis
Tobias Derfuss, M.D., and Ludwig Kappos, M.D., of University Hospital Basel, Switzerland, write in an accompanying editorial that the "rigorously collected data of Shirani and colleagues reinforce the conclusion that the associations between use of interferons and long-term disability, although plausible, remain unproven.
"As Shirani and colleagues suggest, more effective treatment options and better criteria that lead to more accurate selection of patients who might best respond to these treatments are needed. The relatively low progression rate in the untreated contemporary cohort is reassuring because it indicates that despite the unreliable explicit prognostic criteria, neurologists and patients in British Columbia seem to have made the right choices."
(JAMA. 2012;308[3]:290-291. Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Kappos' and Dr. Derfuss' institution receives drug company grants and/or payments for various activities including development of educational presentations, service on speakers bureaus, board memberships, and consultancies.
###
To contact corresponding author Helen Tremlett, Ph.D., call Brian Lin at 604-822-6397 or email brian.lin@ubc.ca. To contact editorial co-author Ludwig Kappos, M.D., email lkappos@uhbs.ch
END
Fewer people died or needed expensive long-term care when their physicians focused on the top risk factors for stroke and dementia, according to research reported in the Journal of the American Heart Association (JAHA). dementia
The primary care doctors in the German study focused on high blood pressure, smoking, high cholesterol, diabetes, irregular heartbeat (atrial fibrillation) and depression. The researchers found that during a five-year period, the need for long-term care was cut 10 percent in women and 9.6 percent in men.
Based on data collected in a comparison ...
Breast cancer mortality statistics in Sweden are consistent with studies that have reported that screening has limited or no impact on breast cancer mortality among women aged 40-69, according to a study published July 17 in the Journal of The National Cancer Institute.
Since 1974, Swedish women aged 40-69 have increasingly been offered mammography screening, with nationwide coverage peaking in 1997. Researchers set out to determine if mortality trends would be reflected accordingly.
In order to determine this, Philippe Autier, M.D., of the International Prevention ...
VANCOUVER – Diagnostic tests are increasingly capable of identifying plaques and tangles present in Alzheimer's disease, yet the disease remains untreatable. Questions remain about how these tests can be used in research studies examining potential interventions to treat and prevent Alzheimer's disease. Experts from the Perelman School of Medicine at the University of Pennsylvania will today participate in a panel at the Alzheimer's Association International Conference 2012 (AAIC 2012) discussing ways to ethically disclose and provide information about test results to asymptomatic ...
Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered.
The finding suggests that a modified version of tPA could provide benefits to patients who have experienced a stroke, without increasing the risk of bleeding.
The results will be published in the Journal of Neuroscience.
"We may have been giving the right medication, for the wrong reason," says senior author Manuel Yepes, MD, associate professor of neurology at Emory University School ...
Radiation from Japan's Fukushima Daiichi nuclear disaster may eventually cause anywhere from 15 to 1,300 deaths and from 24 to 2,500 cases of cancer, mostly in Japan, Stanford researchers have calculated.
The estimates have large uncertainty ranges, but contrast with previous claims that the radioactive release would likely cause no severe health effects.
The numbers are in addition to the roughly 600 deaths caused by the evacuation of the area surrounding the nuclear plant directly after the March 2011 earthquake, tsunami and meltdown.
Recent PhD graduate John Ten ...
BOSTON – A new way of mapping how physicians share patients provides opportunities for improving the quality of medical care and organizing the nature of care delivery, according to researchers from Beth Israel Deaconess Medical Center and Harvard Medical School.
In a study published in the July 18 edition of the Journal of the American Medical Association, researchers suggest this new way of systematically looking at how physicians are organized into patient-sharing networks can shed light on practice variation, aid in the spread of innovation and help form natural groups ...
More children are surviving cancer in Britain than ever before according to new research published in the cancer journal Annals of Oncology [1] today (Wednesday). The improvement in survival has been driven by the increasing numbers taking part in clinical trials since 1977 when the UK Children's Cancer Study Group (UKCCSG) [2] was established.
The UKCCSG's principal aim was to set up a comprehensive portfolio of national and international trials for the majority of children's cancers. As result, between 1978 and 2005 two-thirds of children diagnosed with cancer in Britain ...
It is a cellular component so scarce, some scientists even doubted its existence, and many others gave up searching for its molecular structure. Now a team led by researchers at Johns Hopkins has defined the protein structural composition of mitoKATP, a potassium channel in the mitochondria of the heart and other organs that is known to protect against tissue damage due to a heart attack or stroke. Importantly, the newly found channel strongly improves heart cell survival, demonstrating an essential life-saving role.
In a report to be published in the journal Circulation ...
Johns Hopkins researchers say they have discovered a cause-and-effect relationship between two well-established biological risk factors for schizophrenia previously believed to be independent of one another.
The findings could eventually lead researchers to develop better drugs to treat the cognitive dysfunction associated with schizophrenia and possibly other mental illnesses.
Researchers have long studied the role played in the brain's neurons by the Disrupted-in-Schizophrenia 1 (DISC1) gene, a mutation with one of the strongest links to an increased risk of developing ...
A detailed study of heart muscle function in mice has uncovered evidence to explain why exercise is beneficial for heart function in type 2 diabetes. The research team, led by scientists at the Johns Hopkins University School of Medicine, found that greater amounts of fatty acids used by the heart during stressful conditions like exercise can counteract the detrimental effects of excess glucose and improve the diabetic heart's pumping ability in several ways. The findings also shed light on the complex chain of events that lead to diabetic cardiomyopathy, a form of heart ...
